» Articles » PMID: 19836153

Randomized Comparison of Whole Brain Radiotherapy, 20 Gy in Four Daily Fractions Versus 40 Gy in 20 Twice-daily Fractions, for Brain Metastases

Overview
Specialties Oncology
Radiology
Date 2009 Oct 20
PMID 19836153
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The present study compared the intracranial control rate and quality of life for two radiation fractionation schemes for cerebral metastases.

Methods And Materials: A total of 113 patients with a Eastern Cooperative Oncology Group performance status <3; and stable (>2 months), absent, or concurrent presentation of extracranial disease were randomized to 40 Gy in 20 twice-daily fractions (Arm A) or 20 Gy in four daily fractions (Arm B), stratified by resection status. The European Organization for Research and Treatment of Cancer Quality of Life 30-item questionnaire was administered monthly during Year 1, bimonthly during Year 2, and then every 6 months to Year 5.

Results: The patient age range was 28-83 years (mean 62). Of the 113 patients, 41 had undergone surgical resection, and 74 patients had extracranial disease (31 concurrent and 43 stable). The median survival time was 6.1 months in Arm A and 6.6 months in Arm B, and the overall 5-year survival rate was 3.5%. Intracranial progression occurred in 44% of Arm A and 64% of Arm B patients (p = .03). Salvage surgery or radiotherapy was used in 4% of Arm A patients and 21% of Arm B patients (p = .004). Death was attributed to central nervous system progression in 32% of patients in Arm A and 52% of patients in Arm B (p = .03). The toxicity was minimal, with a minor increase in short-term cutaneous reactions in Arm A. The patients' quality of life was not impaired by the more intense treatment in Arm A.

Conclusion: Intracranial disease control was improved and the quality of life was maintained with 40 Gy in 20 twice-daily fractions. This schema should be considered for better prognosis subgroups of patients with cerebral metastases.

Citing Articles

Neurological symptom management in breast cancer meningeal carcinomatosis.

Takahashi H Transl Breast Cancer Res. 2025; 6:7.

PMID: 39980811 PMC: 11836744. DOI: 10.21037/tbcr-24-47.


Survival and quality of life after first-time diagnosis of brain metastases: a multicenter, prospective, observational study.

Yri O, Astrup G, Karlsson A, van Helvoirt R, Hjermstad M, Husby K Lancet Reg Health Eur. 2025; 49():101181.

PMID: 39807153 PMC: 11728971. DOI: 10.1016/j.lanepe.2024.101181.


Clinical Outcomes of Patients Treated with Short-course Palliative Radiotherapy in the First Year of the COVID-19 Pandemic: A Single Institution Experience.

Jamora K, Cupino N Acta Med Philipp. 2024; 57(8):38-45.

PMID: 39484192 PMC: 11522619. DOI: 10.47895/amp.vi0.4147.


Prognostic Factors and Impact of Therapeutic Intervention in Patients With Brain Metastases at the Initial Presentation.

Ishikawa Y, Teramura S, Nakano H, Ito K, Yamada T Cureus. 2024; 16(5):e60368.

PMID: 38751406 PMC: 11095982. DOI: 10.7759/cureus.60368.


Glasgow prognostic score for assessing the efficacy of whole-brain radiation therapy in cases of recursive partitioning analysis class 2 and class 3 multiple brain metastases: a retrospective study.

Ishikawa Y, Umezawa R, Yamamoto T, Takahashi N, Takeda K, Suzuki Y Acta Neurol Belg. 2023; 124(1):231-239.

PMID: 37747688 PMC: 10874307. DOI: 10.1007/s13760-023-02384-x.